These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34224270)

  • 1. The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.
    Sacks HS
    Ann Intern Med; 2021 Jul; 174(7):JC75. PubMed ID: 34224270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).
    Irfan N; Chagla Z
    Ann Intern Med; 2021 May; 174(5):JC50. PubMed ID: 33939483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.
    Sacks HS
    Ann Intern Med; 2021 Nov; 174(11):JC124. PubMed ID: 34724399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose.
    Granwehr BP
    Ann Intern Med; 2022 May; 175(5):JC52. PubMed ID: 35500261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
    Mercado NB; Zahn R; Wegmann F; Loos C; Chandrashekar A; Yu J; Liu J; Peter L; McMahan K; Tostanoski LH; He X; Martinez DR; Rutten L; Bos R; van Manen D; Vellinga J; Custers J; Langedijk JP; Kwaks T; Bakkers MJG; Zuijdgeest D; Rosendahl Huber SK; Atyeo C; Fischinger S; Burke JS; Feldman J; Hauser BM; Caradonna TM; Bondzie EA; Dagotto G; Gebre MS; Hoffman E; Jacob-Dolan C; Kirilova M; Li Z; Lin Z; Mahrokhian SH; Maxfield LF; Nampanya F; Nityanandam R; Nkolola JP; Patel S; Ventura JD; Verrington K; Wan H; Pessaint L; Van Ry A; Blade K; Strasbaugh A; Cabus M; Brown R; Cook A; Zouantchangadou S; Teow E; Andersen H; Lewis MG; Cai Y; Chen B; Schmidt AG; Reeves RK; Baric RS; Lauffenburger DA; Alter G; Stoffels P; Mammen M; Van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2020 Oct; 586(7830):583-588. PubMed ID: 32731257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    Solforosi L; Kuipers H; Jongeneelen M; Rosendahl Huber SK; van der Lubbe JEM; Dekking L; Czapska-Casey DN; Izquierdo Gil A; Baert MRM; Drijver J; Vaneman J; van Huizen E; Choi Y; Vreugdenhil J; Kroos S; de Wilde AH; Kourkouta E; Custers J; van der Vlugt R; Veldman D; Huizingh J; Kaszas K; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Barouch DH; Böszörményi KP; Stammes MA; Kondova I; Verschoor EJ; Verstrepen BE; Koopman G; Mooij P; Bogers WMJM; van Heerden M; Muchene L; Tolboom JTBM; Roozendaal R; Brandenburg B; Schuitemaker H; Wegmann F; Zahn RC
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33909009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC29. PubMed ID: 33646835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    Heininger U
    N Engl J Med; 2021 Jul; 385(3):288. PubMed ID: 34107178
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply.
    Vandebosch A; Sadoff J; Douoguih M
    N Engl J Med; 2021 Jul; 385(3):288. PubMed ID: 34107179
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine.
    Banerjee S; Sandhu M; Tonzi E; Tambe A; Gambhir HS
    Am J Ther; 2021 Aug; 28(5):e604-e606. PubMed ID: 34469919
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
    Custers J; Kim D; Leyssen M; Gurwith M; Tomaka F; Robertson J; Heijnen E; Condit R; Shukarev G; Heerwegh D; van Heesbeen R; Schuitemaker H; Douoguih M; Evans E; Smith ER; Chen RT;
    Vaccine; 2021 May; 39(22):3081-3101. PubMed ID: 33676782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.
    Paladugu S; Donato AA
    Ann Intern Med; 2020 Jul; 173(2):JC4. PubMed ID: 32687756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines - less obfuscation, more transparency and action.
    Venter WDF; Madhi SA; Nel J; Mendelson M; Van den Heever A; Moshabela M
    S Afr Med J; 2021 Apr; 111(6):515-516. PubMed ID: 34382555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In COVID-19, escalated- vs. prophylactic-dose anticoagulation does not reduce mortality and increases major bleeding.
    Chaudhuri D; Rochwerg B
    Ann Intern Med; 2022 Feb; 175(2):JC18. PubMed ID: 35099996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.
    Tostanoski LH; Wegmann F; Martinot AJ; Loos C; McMahan K; Mercado NB; Yu J; Chan CN; Bondoc S; Starke CE; Nekorchuk M; Busman-Sahay K; Piedra-Mora C; Wrijil LM; Ducat S; Custers J; Atyeo C; Fischinger S; Burke JS; Feldman J; Hauser BM; Caradonna TM; Bondzie EA; Dagotto G; Gebre MS; Jacob-Dolan C; Lin Z; Mahrokhian SH; Nampanya F; Nityanandam R; Pessaint L; Porto M; Ali V; Benetiene D; Tevi K; Andersen H; Lewis MG; Schmidt AG; Lauffenburger DA; Alter G; Estes JD; Schuitemaker H; Zahn R; Barouch DH
    Nat Med; 2020 Nov; 26(11):1694-1700. PubMed ID: 32884153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccines, where do we stand?
    Fischer A
    C R Biol; 2021 Jun; 344(1):43-55. PubMed ID: 34213848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.